Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Athos therapeutics

Request full access

Pioneering the Development of Artificial Intelligence-based Precision Therapeutics for Chronic Inflammatory Diseases

Torrance, United StatesFounded 2019Biotech & Life Sciences

About Athos therapeutics

Athos Therapeutics, a clinical-stage biotechnology company founded in 2019, is focused on developing small-molecule precision therapeutics for immune-mediated diseases and cancer. The company was established by a team with extensive experience in biotechnology and academia: Dimitrios Iliopoulos, Allan J. Pantuck, and Michael Jung. Iliopoulos, the President and CEO, has a background that merges academic research at Harvard and UCLA with business acumen, holding an MBA and certificates in finance, M&A, and AI. His journey from growing up in Greece to becoming a tenured professor at UCLA and now a biotech entrepreneur reflects his long-standing goal of developing new therapies for patients. Pantuck, the Chairman and Chief Medical Officer, is a co-founder of Kite Pharma (acquired by Gilead) and a Professor of Urology at UCLA, bringing deep clinical and regulatory expertise. Jung is a distinguished professor at UCLA and a renowned medicinal chemist behind multi-billion-dollar FDA-approved drugs.

The company's business model centers on its proprietary AI-driven drug discovery platform. This platform integrates multi-omics data from a vast repository of over 35,000 patient samples, sourced through collaborations with institutions like the Cleveland Clinic. By applying machine learning algorithms to this complex biological data, Athos identifies novel drug targets and develops precision small-molecule inhibitors. This technology-first approach aims to accelerate the drug development process, as evidenced by their lead program moving from concept to clinical trial in under four years. The company generates value through the discovery and clinical development of its pipeline assets, with a business strategy geared towards partnerships, licensing, and eventual commercialization of its therapies.

Athos' core product is its advanced drug discovery platform, which comprises several components: RHEA for automated transcriptomics, TETHYS for autonomous proteomics, and DIONE, a deep machine learning framework for patient subtyping. This integrated system, now called "Athos Omics AI," analyzes genetic, protein, and metabolite data to uncover the molecular basis of complex diseases. The platform's primary output is a pipeline of novel drug candidates. The lead asset, ATH-063, is an orally administered small molecule developed for Inflammatory Bowel Disease (IBD) that recently completed a successful Phase 1 clinical trial. The pipeline also includes candidates for other autoimmune diseases like lupus, atopic dermatitis, and Sjögren's syndrome, as well as various cancers, including acute myeloid leukemia (AML). The company's unique selling point is its ability to stratify patients into molecular subtypes, enabling the development of targeted therapies for specific patient populations who are unlikely to respond to existing treatments.

Source: Dealroom company data

At a glance

Status
Operational
Employees
37
Open positions
None listed
Dealroom signal
85.3/100
Industry
Health
Sub-industry
BioTechnology, Health Platform
Sector
Biotechnology, Drug Development, Core AI, Precision Medicine, Spinout, Biotech and Pharma, Techbio
Technology
Artificial Intelligence, Deep Tech
Business model
Manufacturing
Client focus
B2B
Investment activity
1 company, latest May 2023
Capital deployed
$26M
Preferred round
SERIES D

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Feb 2024 $35M $140M Undisclosed ↗
SERIES AOther financing Nov 2021 $15M $60M Undisclosed ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Athos therapeutics website traffic

Latest recorded traffic for Athos therapeutics is 3.1K monthly website visits, down 11.4% over the last three months. Athos therapeutics's team grew 8.8% over the past year.

Latest monthly visits3.1K 3-month web change-11.4% 1-year team growth+8.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Athos therapeutics in the Torrance ecosystem

Live from Dealroom

The Athos therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Other known investors1 additional known investor

  • University of California, Los Angeles
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States88%
🇻🇳 Vietnam8%
🇫🇷 France4%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Athos therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Athos therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.